Whats New in Leiomyosarcoma Research?

Leiomyosarcoma Research Articles and News- Updates:

February 7, 2017:

January 19, 2017:

December 12, 2016:

October 24, 2016:

October 19th, 2016:

October 14, 2016:

  • Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomized, double-blind, placebo-controlled, phase 2 trial. Patients and Families- Click the Link “The Lancet Oncology”   to read the rest of the article.  This is important information to discuss with your oncologist /oncology medical team. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30507-1/abstract

October 10, 2016:

  • Neoadjuvant anthracycline plus ifosfamide chemotherapy was linked to significantly increased survival rates in patients with soft tissue sarcomas located in the torso or extremities who were at high risk of recurrence. Click here for more information.
  • Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Click here for the abstract.

October 07, 2016:

  • Trabectedin Improves PFS vs Best Supportive Care in Sarcoma

    Trabectedin significantly improves progression-free survival in patients with pretreated advanced soft tissue sarcomas.

    Click here for more information.

October 1, 2016:

  • High expression of proteasome activator complex subunit 1 (PSME1) is associated with poor survival in soft tissue leiomyosarcoma patients and might be used to predict the likely course of the disease.
Definitions of a few of the terms in order of their appearance in this article:
Spectrometry –  a measuring instrument for the study of the interaction of matter involving molecules or other material related to the study (and involving wavelength or frequency).
Proteasome –  cellular protein – damaged/degraded
immunoproteasome –  a proteasome assembled in response to pro-inflammatory signals.
Microarrays – molecules (or fragments), usually of DNA or protein, attached in a pattern for use in biochemical or genetic analysis.
Covariates –   known, controlled variables that may affect the outcome of a clinical trial.
Immunohistochemistry –  demonstration of specific antigens (harmful antibodies) in tissues by the use of dyes or fluorescent markers.
Histological –  study of microscopic tissue structures
Biomarker –  a distinctive biological indicator of a disease process –  biochemical, genetic, or molecular characteristic.

Click here for more information on the study.

September 2016:

  • The BMC ( British Journal of Cancer) features an article on molecular classification of uterine leiomyosarcomas. Their data supports the existence of distinct leiomyosarcoma subgroups which are clinically associated with tumor grades. These findings will help advance the classification of leiomyosarcomas and promote more individualized treatments. Click here for the abstract.

August 8, 2016:

  • The Liddy Shriver Sarcoma Initiative is funding a $1 million international collaborative grant for leiomyosarcoma (LMS) research. The two-year project will enlist investigators from France, Germany, and the United States with the aim of identifying new therapies and starting clinical trials for the most prevalent and clinically challenging types of LMS.
  • The Grant Announcement  – “$1 Million Study on Leiomyosarcoma Set to Begin” –http://bit.ly/2bcT1iq

    The Experimental Plan Article – Maximizing Therapeutic Response in Leiomyosarcoma –http://bit.ly/2aSLxR2

For more information, visit the website http://sarcomahelp.org/leiomyosarcoma-collaborative-research.html
July 2016:

  • A study exploring chromosomal abnormalities in uterine smooth muscle tumors found that uterine leiomyomas with abnormal nuclei and leiomyosarcomas are closely related. Click here for the abstract.

May 2016:

  • A study published by the BJC found that antiapoptotic (anti-cell death) Bc1-2 family proteins are highly expressed in soft tissue leiomyosarcomas and inhibition of these proteins increases tumor sensitivity to chemotherapy. Click here for the abstract.

January 2016:

December 2015:

  • https://clinicaltrials.gov/ct2/show/NCT02180867
    • Radiation therapy with or without combination chemotherapy or Pazopanib Hydrochloride before surgery in treating patients with soft tissue sarcomas that can be removed by surgery.
  • Anti-PD1 Antibody Pembrolizumab (MK-3475) –  KEYTRUDA
    • The Sarcoma Alliance for Research through Collaboration (SARC) entered into a Phase II study of Keytruda with Merck Pharmaceutical Company, in collaboration with Dohme Corp., for advanced sarcomas, bone sarcomas, and soft tissue sarcomas – including leiomyosarcoma.
    • The study continues with no further recruitment of participants at this time.  The estimated completion date for final data collection for “primary outcome” measure is December 2016.
  • The clinical, research, and social value of autopsy after any cancer death: A perspective from the Children’s Oncology Group Soft Tissue Sarcoma Committee

November 2015:

October 2015:

  • Yondelis (Trabectedin) Approved by the FDA for Leiomyosarcoma and Liposarcoma.
    • The chemotherapy drug Trabectedin (Yondelis) was approved by the FDA to treat Leiomyosarcoma and Liposarcoma,  deemed unresectable, yet previously treated with chemotherapy that contained the drug anthracycline.
    • Yondelis was evaluated in clinical studies involving 518 patients.  Those who were given Yondelis had a cancer progression that stopped for an average of 4.2 months, compared to an average of 1.5 months for the patient group members who took another anti-cancer drug.
    • The most common side effects of Yondelis include nausea, fatigue, vomiting, diarrhea, constipation, loss of appetite, shortness of breath, headache, and tissue swelling.  The drug’s label has an additional list of side effects as well.   Yondelis is marketed by Janssen Products.

Reaching For the Cure Together